摘要
神经鞘氨醇类似物FTY720是一种新型的免疫抑制剂,可用于器官移植的抗排斥反应以及自身免疫性疾病、肿瘤和炎症等的治疗,目前在肾移植排斥反应的治疗方面已进入Ⅲ期临床试验,在多发性硬化症的治疗方面已进入Ⅱ期临床试验。综述FTY720及其类似物的研究进展。
FTY720, 2-amino-2-[2-（4-octylphenyl） ethyl] propane-1, 3-diol hydrochloride, is an oral sphingosine-1-phosphate receptor agonist and immunosuppressant being developed for anti-rejection in organ transplantation, autoimmune disorders, tumor and inflammatory diseases. Phase Ⅲ clinical trial of FTY720 in the treatment of graft rejection episodes after renal transplantation and phase Ⅱ clinical trial in the treatment of multiple sclerosis are underway. The recent developments of FTY720 and its analogs were reviewed.
出处
《药学进展》
CAS
2008年第7期309-313,共5页
Progress in Pharmaceutical Sciences
